Table 2.

Clinical Outcomes in the FAST-1 and FAST-2 Trials, According to Study Group.^*

Outcome	FAST-1			FAST-2
	Icatibant (N = 27)	Placebo (N = 29)	P Value	Icatibant (N = 36)	Tranexamic Acid (N = 38)	P Value
Time to clinically significant relief of the index symptom (primary end point) — hr			0.14			<0.001
Median	2.5	4.6		2.0	12.0
IQR	1.1–6.0	1.8–10.2		1.0–3.5	3.5–25.4
Time to first symptom improvement — hr
According to patient			<0.001			<0.001
Median	0.8	16.9		0.8	7.9
IQR	0.5–2.0	3.2–NA		0.4–1.4	1.1–NA
According to investigator			<0.001			<0.001
Median	1.0	5.7		1.5	6.9
IQR	0.8–2.0	2.0–11.2		0.7–3.0	4.0–13.8
Time to almost complete relief of symptoms — hr			0.08			<0.001
Median	8.5	19.4		10.0	51.0
IQR	2.5–31.5	10.2–55.7		2.8–23.2	12.0–79.5
Clinically significant relief of the index symptom at 4 hr after start of study drug — % (95% CI)	67 (46–84)	46 (28–66)†	0.18	80 (63–92)†	31 (16–48)‡	<0.001

^*NA denotes not available, CI confidence interval, and IQR interquartile range.

^†Data are missing for one patient.

^‡Data are missing for two patients.